Sai Parenterals IPO: ₹409 Crore Issue Opens March 24, 2026

Introduction to Sai Parenterals IPO

Hyderabad-based pharmaceutical firm Sai Parenterals Limited is set to launch its Initial Public Offering (IPO) on March 24, 2026. The public issue, aiming to raise approximately ₹408.79 crore, will be open for subscription until March 27, 2026. The company is a developer, manufacturer, and supplier of a wide range of pharmaceutical formulations. The IPO comprises a combination of a fresh issue of equity shares and an offer for sale (OFS) by existing shareholders. The price band for the issue has been fixed at ₹372 to ₹392 per equity share. The company plans to list its shares on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).

IPO Timeline and Key Dates

The IPO process follows a set schedule from the opening of the subscription to the final listing of shares. Anchor investors will have the opportunity to place their bids on March 23, 2026, a day before the issue opens to the public. The basis of allotment for shares is expected to be finalized by March 30, 2026. Following this, refunds for unallotted applications and the credit of shares to the demat accounts of successful bidders are scheduled for April 1, 2026. The shares are anticipated to debut on the stock exchanges on April 2, 2026.

Issue Structure and Size

The total issue size of the IPO is ₹408.79 crore. This is structured as a book-built issue and includes both a fresh issue and an offer for sale. The fresh issue component consists of 72,70,408 equity shares, aiming to raise ₹285 crore at the upper end of the price band. The proceeds from the fresh issue will be utilized by the company for its strategic growth initiatives. The offer for sale (OFS) component involves the sale of 31,57,880 equity shares by existing shareholders, aggregating to approximately ₹123.79 crore. Shareholders participating in the OFS include Vikasa India EIF I Fund and several individual investors.

Price Band, Lot Size, and Investment Details

Sai Parenterals has set the IPO price band at ₹372 to ₹392 per share, with a face value of ₹5 per share. The minimum application size, or lot size, is 38 shares. For retail investors, this translates to a minimum investment of ₹14,896 at the upper price band of ₹392. The maximum investment for a retail investor is capped at 13 lots, which amounts to 494 shares for a total of ₹1,93,648. For High Net-worth Individuals (HNIs), the investment requirements are higher. Small HNIs (sNII) must apply for a minimum of 14 lots (532 shares) for ₹2,08,544, while big HNIs (bNII) need to bid for a minimum of 68 lots (2,584 shares), amounting to ₹10,12,928.

Objectives of the Fresh Issue

The company intends to use the net proceeds from the fresh issue of ₹285 crore for several key corporate purposes. A significant portion, ₹110.80 crore, is allocated for expanding and upgrading its manufacturing facilities. Another ₹18.02 crore will be used to establish a new research and development (R&D) center. The company also plans to repay or prepay certain borrowings amounting to ₹14.30 crore. A sum of ₹33 crore is earmarked for working capital requirements, and ₹35.64 crore will be invested in its Singapore-based subsidiary, Sai Parenterals Pte Limited. The remaining funds will be used for general corporate purposes.

Company Profile and Business Operations

Sai Parenterals Limited has a diverse product portfolio covering multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, and gastroenterology. Its products are available in various dosage forms such as injections, tablets, capsules, liquid orals, and ointments. The company's client base is varied, comprising central and state government agencies in India, other pharmaceutical companies, private and government hospitals, and super stockists. This diverse market reach provides a stable revenue stream and reduces dependency on any single channel.

Financial Performance and Valuation

For the fiscal year 2025, Sai Parenterals reported a total income of ₹163.74 crore and a net profit of ₹14.43 crore. For the six-month period ending September 2025, the company's income stood at ₹89.43 crore with a net profit of ₹7.76 crore. Based on the upper price band of ₹392, the post-issue market capitalization of the company is estimated to be around ₹1,731.83 crore. The price-to-earnings (P/E) ratio, based on FY2025 earnings, is calculated at approximately 72.19x, which is higher than the industry average P/E of 62.29x. This premium valuation suggests high growth expectations from the company.

Investor Allocation and Grey Market Premium

The IPO has a reserved quota for different investor categories. 50% of the issue is reserved for Qualified Institutional Buyers (QIBs), 35% is allocated for retail individual investors, and the remaining 15% is set aside for Non-Institutional Investors (NIIs). Ahead of its opening, the Grey Market Premium (GMP) for the Sai Parenterals IPO was reported at ₹0. This indicates that shares were not trading at a premium in the unofficial market, suggesting a listing price close to the issue price.

Conclusion

The Sai Parenterals IPO presents an opportunity for investors to participate in a growing pharmaceutical formulations company. The issue, with a total size of ₹408.79 crore, is strategically aimed at funding capacity expansion, R&D, and debt reduction. Investors should consider the company's financial track record, growth plans, and the premium valuation before subscribing. The public offering will be open from March 24 to March 27, 2026, with the listing scheduled for April 2, 2026.